Skip to main content

Search Videos and More

Showing 133 - 144 of 162 results

Previous| 1... 11 | 12 | 13 ...14 |Next

From a medical cardiologist’s perspective, how do the threshold-setting targets of LDL-C levels of 70 mg/dL apply to PCSK9-based treatment for CV risk reduction? Did the guidelines emphasize sufficiently, the results of the CV outcome trials?

From a medical cardiologist’s perspective, how do the threshold-setting targets of LDL-C levels of 70 mg/dL apply to PCSK9-based treatment for CV risk reduction? Did the guidelines emphasize sufficiently, the results of the CV outcome trials?

What should the “threshold” of 70 mg/dL identified in the AHA Guidelines mean to the medical or preventive cardiologist in his/her aspiration to optimize CV risk reduction in high-risk patients with a history of ACS or related high-risk features?

What should the “threshold” of 70 mg/dL identified in the AHA Guidelines mean to the medical or preventive cardiologist in his/her aspiration to optimize CV risk reduction in high-risk patients with a history of ACS or related high-risk features?

Do you use different LDL-C levels in persons with diabetes to justify initiation of PCSK9 inhibitors? Is the presence of ACS required or symptomatic ASCVD required to triage them into PCSK9-based treatment?

Do you use different LDL-C levels in persons with diabetes to justify initiation of PCSK9 inhibitors? Is the presence of ACS required or symptomatic ASCVD required to triage them into PCSK9-based treatment?

In light of the effectiveness and safety in post-ACS patients of the “ultra-low” levels of LDL-C achieved in the ODYSSEY Outcomes and FOURIER Trials, how has that shaped your clinical perspective on the role of PCSK9 inhibitors in high-risk patients?

In light of the effectiveness and safety in post-ACS patients of the “ultra-low” levels of LDL-C achieved in the ODYSSEY Outcomes and FOURIER Trials, how has that shaped your clinical perspective on the role of PCSK9 inhibitors in high-risk patients?

From a safety perspective how do you counsel your patients in whom you are beginning PCSK9 inhibitor therapy?

From a safety perspective how do you counsel your patients in whom you are beginning PCSK9 inhibitor therapy?

What does the pharmacoeconomic landscape currently look like for PCSK9 inhibition, especially in light of the recent price reductions for alirocumab and evolocumab?

What does the pharmacoeconomic landscape currently look like for PCSK9 inhibition, especially in light of the recent price reductions for alirocumab and evolocumab?

In the Type 2 diabetes population that you manage in your, what percentage of patients do you estimate do not achieve risk-appropriate LDL-C for any number of reasons? Is it as high as 10%, as reported in by some diabetes experts?

In the Type 2 diabetes population that you manage in your, what percentage of patients do you estimate do not achieve risk-appropriate LDL-C for any number of reasons? Is it as high as 10%, as reported in by some diabetes experts?

From the perspective of a lipid and atherosclerosis specialist, assuming that the barriers to PCSK9 inhibitors are reduced, which patients at risk for—or with confirmed—ASCVD represent the best, risk-directed candidates for LDL-C lowering?

From the perspective of a lipid and atherosclerosis specialist, assuming that the barriers to PCSK9 inhibitors are reduced, which patients at risk for—or with confirmed—ASCVD represent the best, risk-directed candidates for LDL-C lowering?

What is your experience deploying PCSK9 inhibitors in the clinic, and what are the most reliable and actionable triggers for deploying this program for CV risk reduction? And predictably achieving reimbursement and payor support for this therapy?

What is your experience deploying PCSK9 inhibitors in the clinic, and what are the most reliable and actionable triggers for deploying this program for CV risk reduction? And predictably achieving reimbursement and payor support for this therapy?

Are you finding it easier to get authorization for reimbursement and approval of PCSK9 inhibitors now that prices have come down and we have seen clear outcome benefits in both major trials?

Are you finding it easier to get authorization for reimbursement and approval of PCSK9 inhibitors now that prices have come down and we have seen clear outcome benefits in both major trials?

Although 70 mg/dL is the target threshold identified by both ESC and AHA, should the interventionalist, in a patient who has just undergone a PCI and has an LDL-C of 69 mg/dL, be considered adequately CV risk-mitigated?

Although 70 mg/dL is the target threshold identified by both ESC and AHA, should the interventionalist, in a patient who has just undergone a PCI and has an LDL-C of 69 mg/dL, be considered adequately CV risk-mitigated?

Can you discuss the importance of the two principal PSCK9 CV outcome trials—ODYSSEY Outcomes and FOURIER—and how they are similar and in what ways they are different? What are the implications for the patient with T2D and ASCVD?

Can you discuss the importance of the two principal PSCK9 CV outcome trials—ODYSSEY Outcomes and FOURIER—and how they are similar and in what ways they are different? What are the implications for the patient with T2D and ASCVD?

Showing 133 - 144 of 162 results

Previous| 1... 11 | 12 | 13 ...14 |Next